Figure 4

Impaired G2/M or S-phase arrest in NSCLC TICs after IR and cisplatin treatment. (a) Proliferation of IR and cisplatin-treated H125 and A549 bulk cells and TICs measured by CFSE labeling. The number of cell divisions since drug treatment (i.e. 72 h) is presented for bulk cells and TICs. (b–c) Cell cycle distribution of H125 and A549 bulk cells and TICs after 8 Gy IR and 1 or 10 μM cisplatin treatment. (b) Proportion of cells in the G2/M phase 24 h post IR. (c) Upper panel: Proportion of cells in the S phase after 24 h of continuous cisplatin treatment. Lower panel: Proportion of cells in the G2/M phase after 48 h of continuous cisplatin treatment. *P<0.05; **P<0.01